Bimergen Energy Corporation (NYSEAMERICAN:BESS – Get Free Report)’s share price crossed above its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $2.54 and traded as high as $2.80. Bimergen Energy shares last traded at $2.70, with a volume of 559,079 shares traded.
Analyst Upgrades and Downgrades
Separately, Noble Financial initiated coverage on Bimergen Energy in a research report on Thursday. They set an “outperform” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Buy”.
Check Out Our Latest Analysis on Bimergen Energy
Bimergen Energy Stock Up 14.4%
The firm has a market cap of $19.17 million, a price-to-earnings ratio of -2.03 and a beta of 2.64. The stock’s fifty day moving average is $2.54.
Hedge Funds Weigh In On Bimergen Energy
An institutional investor recently bought a new position in Bimergen Energy stock. State Street Corp purchased a new stake in Bimergen Energy Corporation (NYSEAMERICAN:BESS – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,200 shares of the company’s stock, valued at approximately $55,000. State Street Corp owned 0.19% of Bimergen Energy at the end of the most recent quarter.
Bimergen Energy Company Profile
Spine Injury Solutions, Inc provides a suite of revolutionary electrical power generation technologies. The company intends to offer Evirontek Integrated Platform to the cryptocurrency mining industry to reduce the exorbitant high cost of electricity. It also provides spine injury diagnostic services; and owns, develops, and leases the Quad Video Halo video recording system used to record medical procedures. The company is based in Costa Mesa, California.
Read More
- Five stocks we like better than Bimergen Energy
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AIāThese 5 Stocks Are Getting Paid
Receive News & Ratings for Bimergen Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bimergen Energy and related companies with MarketBeat.com's FREE daily email newsletter.
